Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate versus ezetimibe versus combination therapy in type IIb dyslipidemia with metabolic syndrome features
2004-002408-13Phase 3Completed
- Sponsor
- Fournier
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in combined dyslipidaemia and cardiometabolic risk (CMR) comparing Fenofibrate monotherapy, Ezetimibe monotherapy and Fenofibrate + ezetimibe combination (3 arms). Primary endpoints: Percent change in triglycerides and Percent change in HDL cholesterol. Started Dec 2004; status: completed.
02
Drugs
fenofibrateezetimibe
03
Conditions
combined dyslipidaemiacardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2004-002408-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002408-13.